Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease. 
Low-dose valganciclovir
Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease. 
Liver transplantation recipients
Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease. 
Cytomegalovirus prophylaxis
Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease. 
intermediate-risk liver transplantation recipients
Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease.  The primary endpoint was CMV disease at 1 year after transplant.  CMV disease occurred in only 9 (5%) patients, similar to rates in previous studies of LTRs receiving high-dose VGCV.  In conclusion, low-dose VGCV was safe and effective for prevention of CMV disease in our cohort of 200 R+ LTR and should be considered as an option in future guidelines. 
CMV disease
Median Model for End-Stage Liver Disease score was 22 (IQR, 14-31), and 178 (89%) patients received deceased donor transplants. 
Model for End-Stage Liver Disease score
Median Model for End-Stage Liver Disease score was 22 (IQR, 14-31), and 178 (89%) patients received deceased donor transplants. 
Deceased donor transplants
Premature VGCV discontinuation and granulocyte-colony stimulating factor use were infrequent and not significantly different between the 2 groups. 
Granulocyte-colony stimulating factor use